A topical fixed-dose combination therapy for acne vulgaris, combining the keratolytic and antibacterial action of benzoyl peroxide with the antibiotic activity of clindamycin. It is a first-line treatment for mild to moderate inflammatory and non-inflammatory acne, offering synergistic efficacy with a reduced risk of bacterial resistance compared to clindamycin monotherapy.
Adult: Apply a thin layer to the entire affected area(s) once daily, preferably in the evening. Start with alternate-day application if irritation occurs.
Note: 1. Wash and gently pat dry the affected area. 2. Apply a pea-sized amount for the entire face (or a thin layer to other areas). 3. Avoid contact with eyes, lips, mouth, nostrils, and mucous membranes. 4. Wash hands after application. 5. May be used under non-comedogenic moisturizer/sunscreen if needed.
The combination exerts a dual antibacterial and comedolytic action. Benzoyl peroxide is a potent oxidizing agent with bactericidal activity against Cutibacterium acnes (C. acnes) and mild keratolytic and comedolytic properties. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis, reducing C. acnes colonization and inflammatory mediators. Together, they provide a broader antimicrobial spectrum and reduce the potential for clindamycin resistance.
Pregnancy: Category C (US FDA). Animal reproduction studies have not been conducted with the combination. Systemic absorption is minimal, but use only if clearly needed and under medical supervision. Avoid large areas or prolonged use.
Driving: No effect on ability to drive or use machines.
| Topical Erythromycin | Antagonistic pharmacological interaction; reduced efficacy of both agents. | Major |
| Topical Tretinoin or other Retinoids | Potential for increased skin irritation and dryness. Recommend separating application times (e.g., retinoid at night, this combination in morning). | Moderate |
| Topical Dapsone | Benzoyl peroxide may cause temporary local yellow-orange discoloration of skin when used with dapsone gel. | Minor |
| Neuromuscular blocking agents (e.g., Pancuronium) | Systemic clindamycin may enhance neuromuscular blockade. Risk with topical use is theoretical and extremely low. | Theoretical |
Same composition (Benzoyl Peroxide (2.5% w/w) + Clindamycin (1% w/w)), different brands: